B7H1 Expression and Epithelial-To-Mesenchymal Transition Phenotypes on Colorectal Cancer Stem-Like Cells

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2015 Aug 19

PMID 26284927

Citations 43

Authors

Yidan Zhi

Zhirong Mou

Jun Chen

Yujun He

Hui Dong

Xiaolan Fu

Yuzhang Wu

Affiliations

Soon will be listed here.

Abstract

Cancer stem cells (CSCs) can invade and metastasize by epithelial-to-mesenchymal transition (EMT). However, how they escape immune surveillance is unclear. B7H1 is crucial negative co-stimulatory molecule but little information about whether it works in CSCs. Therefore, we determined the expression of B7H1 and EMT-associated markers in colorectal cancer stem-like cells to investigate a possible immunoevasion way of CSCs. We enriched CD133+ colorectal cancer cells which manifested the CSCs-like properties such as higher levels of other stem cell markers Oct-4 and Sox-2, tumor sphere forming ability and more tumorigenic in NOD/SCID mice. These CD133+ cells possess EMT gene expression profile including higher level of Snail, Twist, vimentin, fibronectin and lower level of E-cadherin. Moreover, CD133+ cells in both cell line and colorectal cancer tissues expressed high level of negative co-stimulate molecule B7H1. Furthermore, some B7H1+ cancer cells also showed the characteristic of EMT, indicating EMT cells could escape immune attack during metastasis. B7H1 expression and EMT phenotypes on CSCs indicates a possible immunoevasion way.

Citing Articles

Cancer stem cells and niches: challenges in immunotherapy resistance.

Pan Y, Yuan C, Zeng C, Sun C, Xia L, Wang G Mol Cancer. 2025; 24(1):52.

PMID: 39994696 PMC: 11852583. DOI: 10.1186/s12943-025-02265-2.

BRAFV600E/pTERT double mutated papillary thyroid cancers exhibit immune gene suppression.

Sigarteu Chindris A, Rivera M, Ma Y, Nair A, Liu Y, Wang X Front Endocrinol (Lausanne). 2024; 15:1440722.

PMID: 39717106 PMC: 11663634. DOI: 10.3389/fendo.2024.1440722.

Multidimensional analysis of tumor stem cells: from biological properties, metabolic adaptations to immune escape mechanisms.

Han H, He T, Wu Y, He T, Zhou W Front Cell Dev Biol. 2024; 12:1441081.

PMID: 39184916 PMC: 11341543. DOI: 10.3389/fcell.2024.1441081.

Crosstalk between colorectal CSCs and immune cells in tumorigenesis, and strategies for targeting colorectal CSCs.

Zhao Q, Zong H, Zhu P, Su C, Tang W, Chen Z Exp Hematol Oncol. 2024; 13(1):6.

PMID: 38254219 PMC: 10802076. DOI: 10.1186/s40164-024-00474-x.

Cancer Stem Cells in Colorectal Cancer: Implications for Targeted Immunotherapies.

Turki Jalil A, Abdulhadi M, Al Jawadri A, Talib H, Al-Azzawi A, Zabibah R J Gastrointest Cancer. 2023; 54(4):1046-1057.

PMID: 37247115 DOI: 10.1007/s12029-023-00945-0.

References

Biddle A, Mackenzie I . Cancer stem cells and EMT in carcinoma. Cancer Metastasis Rev. 2012; . DOI: 10.1007/s10555-012-9345-0. View

Navarro-Alvarez N, Kondo E, Kawamoto H, Hassan W, Yuasa T, Kubota Y . Isolation and propagation of a human CD133(-) colon tumor-derived cell line with tumorigenic and angiogenic properties. Cell Transplant. 2010; 19(6):865-77. PMC: 2957535. DOI: 10.3727/096368910X508997. View

Cao Y, Zhang L, Kamimura Y, Ritprajak P, Hashiguchi M, Hirose S . B7-H1 overexpression regulates epithelial-mesenchymal transition and accelerates carcinogenesis in skin. Cancer Res. 2010; 71(4):1235-43. DOI: 10.1158/0008-5472.CAN-10-2217. View

Singh A, Settleman J . EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010; 29(34):4741-51. PMC: 3176718. DOI: 10.1038/onc.2010.215. View

Kudo-Saito C, Shirako H, Takeuchi T, Kawakami Y . Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell. 2009; 15(3):195-206. DOI: 10.1016/j.ccr.2009.01.023. View

Zhang Y, Zhang J, Xu K, Xiao Z, Sun J, Xu J . PTEN/PI3K/mTOR/B7-H1 signaling pathway regulates cell progression and immuno-resistance in pancreatic cancer. Hepatogastroenterology. 2014; 60(127):1766-72. View

Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, Mcdermott D . Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26):2443-54. PMC: 3544539. DOI: 10.1056/NEJMoa1200690. View

Kong D, Li Y, Wang Z, Sarkar F . Cancer Stem Cells and Epithelial-to-Mesenchymal Transition (EMT)-Phenotypic Cells: Are They Cousins or Twins?. Cancers (Basel). 2011; 3(1):716-29. PMC: 3106306. DOI: 10.3390/cancers30100716. View

Kalluri R, Weinberg R . The basics of epithelial-mesenchymal transition. J Clin Invest. 2009; 119(6):1420-8. PMC: 2689101. DOI: 10.1172/JCI39104. View

10.

Zhu L, Hu Y, Yang C, Xu X, Ning T, Wang Z . Snail overexpression induces an epithelial to mesenchymal transition and cancer stem cell-like properties in SCC9 cells. Lab Invest. 2012; 92(5):744-52. DOI: 10.1038/labinvest.2012.8. View

11.

Shmelkov S, Butler J, Hooper A, Hormigo A, Kushner J, Milde T . CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest. 2008; 118(6):2111-20. PMC: 2391278. DOI: 10.1172/JCI34401. View

12.

Alonso M, Diez-Valle R, Manterola L, Rubio A, Liu D, Cortes-Santiago N . Genetic and epigenetic modifications of Sox2 contribute to the invasive phenotype of malignant gliomas. PLoS One. 2011; 6(11):e26740. PMC: 3206066. DOI: 10.1371/journal.pone.0026740. View

13.

Dalerba P, Clarke M . Cancer stem cells and tumor metastasis: first steps into uncharted territory. Cell Stem Cell. 2008; 1(3):241-2. DOI: 10.1016/j.stem.2007.08.012. View

14.

Frank N, Schatton T, Frank M . The therapeutic promise of the cancer stem cell concept. J Clin Invest. 2010; 120(1):41-50. PMC: 2798700. DOI: 10.1172/JCI41004. View

15.

OBrien C, Pollett A, Gallinger S, Dick J . A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2006; 445(7123):106-10. DOI: 10.1038/nature05372. View

16.

Ben-Porath I, Thomson M, Carey V, Ge R, Bell G, Regev A . An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet. 2008; 40(5):499-507. PMC: 2912221. DOI: 10.1038/ng.127. View

17.

Hollier B, Evans K, Mani S . The epithelial-to-mesenchymal transition and cancer stem cells: a coalition against cancer therapies. J Mammary Gland Biol Neoplasia. 2009; 14(1):29-43. DOI: 10.1007/s10911-009-9110-3. View

18.

Wen K, Fu Z, Wu X, Feng J, Chen W, Qian J . Oct-4 is required for an antiapoptotic behavior of chemoresistant colorectal cancer cells enriched for cancer stem cells: effects associated with STAT3/Survivin. Cancer Lett. 2013; 333(1):56-65. DOI: 10.1016/j.canlet.2013.01.009. View

19.

LaBarge M, Bissell M . Is CD133 a marker of metastatic colon cancer stem cells?. J Clin Invest. 2008; 118(6):2021-4. PMC: 2391070. DOI: 10.1172/JCI36046. View

20.

Mani S, Guo W, Liao M, Eaton E, Ayyanan A, Zhou A . The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4):704-15. PMC: 2728032. DOI: 10.1016/j.cell.2008.03.027. View